Rosiglitazone modifies HDL structure and increases HDL-apo AI synthesis and catabolic rates

Clinica Chimica Acta

Volumn 401, Issue 1-2, 2009, Pages 37-41

  Carreón Torres, Elizabeth ^a   Rendón Sauer, Karla ^a   Monter Garrido, Mariana ^a   Toledo Ibelles, Paola ^a   Gamboa, Ricardo ^a   Menjivar, Marta ^b   López Marure, Rebeca ^a   Luc, Gerald ^c   Fievet, Catherine ^c   Cruz, David ^a   Vargas Alarcón, Gilberto ^a   Pérez Méndez, Oscar ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUT PASTEUR DE LILLE   (France)

Author keywords

HDL subclasses; Lipoprotein turnover; Paraoxonase 1; Thiazolidinediones

Indexed keywords

APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 3; IODINE 125; PHENYLACETIC ACID; PHOSPHOLIPID DERIVATIVE; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL COMPOSITION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME SUBSTRATE; LIPOPROTEIN BLOOD LEVEL; MALE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; RABBIT; SPECTROPHOTOMETRY;

ANIMALS; APOLIPOPROTEIN A-I; ARYLDIALKYLPHOSPHATASE; BLOOD GLUCOSE; CHOLESTEROL, HDL; HYPOGLYCEMIC AGENTS; MALE; PPAR GAMMA; RABBITS; THIAZOLIDINEDIONES; TRIGLYCERIDES;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 58549111382     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.11.003     Document Type: Article

References (35)

1. Assmann G., Schulte H., von Eckardstein A., and Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124 Suppl (1996) S11-20
2. Bloomfield R.H., Davenport J., Babikian V., et al. VA-HIT Study Group. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 103 (2001) 2828-2833
3. Feig J.E., Shamir R., and Fisher E.A. Atheroprotective effects of HDL: beyond reverse cholesterol transport. Curr Drug Targets 9 (2008) 196-203
4. Williams P.T., Krauss R.M., Nichols A.V., Vranizan K.M., and Wood P.D. Identifying the predominant peak diameter of high-density and low-density lipoproteins by electrophoresis. J Lipid Res 31 (1990) 1131-1139
5. Tian L., Wu X., Fu M., Qin Y., Xu Y., and Jia L. Relationship between plasma apolipoproteinB concentrations, apolipoproteinB/apolipoproeinA-I and HDL subclasses distribution. Clin Chim Acta 388 (2008) 148-155
6. Deakin S., Leviev I., Gomaraschi M., Calabresi L., Franceschini G., and James R.W. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J Biol Chem 277 (2002) 4301-4308
7. Kontush A., Chantepie S., and Chapman M.J. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 23 (2003) 1881-1888
8. Baldi S., Frascerra S., Ferrannini E., and Natali A. LDL resistance to oxidation: effects of lipid phenotype, autologous HDL and alanine. Clin Chim Acta 379 (2007) 95-100
9. Castro G.R., and Fielding C.J. Early incorporation of cell-derived cholesterol into pre-ß-migrating high density lipoprotein pathway. Biochemistry 27 (1988) 25-29
10. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., and La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 101 (1998) 1581-1590
11. Akiyama T.E., Sakai S., Lambert G., et al. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol 22 (2002) 2607-2619
12. Malerod L., Sporstol M., Juvet L.K., Mousavi A., Gjoen T., and Berg T. Hepatic scavenger receptor class B, type I is stimulated by peroxisome proliferator-activated receptor gamma and hepatocyte nuclear factor alpha. Biochem Biophys Res Commun 305 (2003) 557-565
13. Herz M., Johns D., Reviriego J., et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther 25 (2003) 1074-1095
14. Carreón-Torres E., Juárez-Meavepeña M., Cardoso-Saldaña G., et al. Pioglitazone increases the fractional catabolic and production rates of high-density lipoproteins apo AI in the New Zealand White Rabbit. Atherosclerosis 181 (2005) 233-240
15. Huesca-Gómez C., Franco M., Luc G., et al. Chronic hypothyroidism induces abnormal structure of high-density lipoproteins and impaired kinetics of apolipoprotein A-I in the rat. Metabolism 51 (2002) 443-450
16. Elkhalil L., Majd Z., Bakir R., et al. Fish-eye disease: structural and in vivo metabolic abnormalities of high-density lipoproteins. Metabolism 46 (1997) 474-483
17. Goldberg R.B., Kendall D.M., and Deeg M.A. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 (2005) 1547-1554
18. Deeg M.A., Buse J.B., Goldberg R.B., et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 30 (2007) 2458-2464
19. Lamarche B., Uffelman K.D., Steiner G., Barrett P.H., and Lewis G. Analysis of particle size and lipid composition as determinants of the metabolic clearance of human high density lipoproteins in a rabbit model. J Lipid Res 39 (1998) 1162-1172
20. Lewis G.F., Lamarche B., Uffelman K.D., et al. Clearance of postprandial and lipolytically modified human HDL in rabbits and rats. J Lipid Res 38 (1997) 1771-1778
21. Pérez-Méndez O., Alvarez-Salcedo P., Carreón Torres E., et al. Palmitic acid in HDL is associated to low apo A-I fractional catabolic rates in vivo. Clin Chim Acta 378 (2007) 53-58
22. Huesca-Gómez C., Carreón-Torres E., Nepomuceno-Mejía T., et al. Contribution of cholesteryl ester transfer protein and lecithin: cholesterol acyl tranferase to HDL size distribution. Endocr Res 30 (2004) 403-415
23. Bilheimer D.W., Eisenberg D., and Levy R.I. The metabolism of very low density lipoproteins. preliminary in vitro and in vivo observations. Biochim Biophys Acta 260 (1972) 212-221
24. Rashid S., Uffelman K.D., Barrett P.H., and Lewis G.F. Effect of atorvastatin on high-density lipoprotein apolipoprotein A-I production and clearance in the New Zealand white rabbit. Circulation 106 (2002) 2955-2960
25. Brousseau M.E., Santamarina-Fojo S., Zech L.A., et al. Hyperalphalipoproteinemia in human lecithin cholesterol acyltransferase transgenic rabbits. In vivo apolipoprotein A-I catabolism is delayed in a gene dose-dependent manner. J Clin Invest 97 (1996) 1844-1851
26. Lowry O.H., Rosebrough H.J., and Farr A.L. Protein measurement with the folin phenol reagent. J Biol Chem 193 (1951) 265-275
27. Tailleux A., Torpier G., Caron B., et al. Immunological properties of apoB-containing lipoprotein particles in human atherosclerotic arteries. J Lipid Res 34 (1993) 719-728
28. Gan K.L., Smolen A., Eckerson H.W., and La Du B.N. Protein purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 19 (1991) 100-106
29. Sakamoto J., Kimura H., Moriyama S., et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 278 (2000) 704-711
30. Pérez-Méndez O., Torres-Tamayo M., Posadas-Romero C., et al. Abnormal HDL subclasses distribution in overweight children with insulin resistance or type 2 diabetes mellitus. Clin Chim Acta 376 (2007) 17-22
31. Garvey W.T., Kwon S., Zheng D., et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52 (2003) 453-642
32. Pietzsch J., Julius U., Nitzsche S., and Hanefeld M. In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Diabetes 47 (1998) 1928-1934
33. Deeg M.A., and Tan M.H. Pioglitazone vs rosiglitazone: effects on lipids, lipoproteins, and apolipoproteins in head-to-head randomized clinical studies. PPAR Res (2008) 520465 2008
34. Kozarsky K.F., Donahee M.H., Rigotti A., Iqbal S.N., Edelman E.R., and Krieger M. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature 387 (1997) 414-417
35. Webb N.R., Cai L., and Ziemba K.S. The fate of HDL particles in vivo after SR-BI-mediated selective lipid uptake. J Lipid Res 43 (2002) 1890-1898